United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Healthcare Industry News Abbott’s Volt PFA system delivers strong 12-month AFib outcomes, heart rhythm society 2025 data reveal Explore how Abbott’s Volt™ PFA System is redefining AFib treatment with groundbreaking 12-month results — see why it’s a game-changer in cardiac care. byPallavi MadhirajuApril 27, 2025